Isorhapontigenin protects against doxorubicin-induced cardiotoxicity
Acta Pharmaceutica Sinica B
; (6): 680-693, 2021.
Article
in En
| WPRIM
| ID: wpr-881162
Responsible library:
WPRO
ABSTRACT
As an effective anticancer drug, the clinical limitation of doxorubicin (Dox) is the time- and dose-dependent cardiotoxicity. Yes-associated protein 1 (YAP1) interacts with transcription factor TEA domain 1 (TEAD1) and plays an important role in cell proliferation and survival. However, the role of YAP1 in Dox-induced cardiomyopathy has not been reported. In this study, the expression of YAP1 was reduced in clinical human failing hearts with dilated cardiomyopathy and Dox-induced
Full text:
1
Index:
WPRIM
Language:
En
Journal:
Acta Pharmaceutica Sinica B
Year:
2021
Type:
Article